<DOC>
	<DOCNO>NCT00168519</DOCNO>
	<brief_summary>The purpose project determine whether glucose metabolism improve administering substance ( nitric oxide donor ) normally release muscle exercise .</brief_summary>
	<brief_title>Contraction ( Exercise ) Mediated Glucose Uptake Therapeutic Target Type 2 Diabetes</brief_title>
	<detailed_description>Aim 1 : To determine whether acute infusion sodium nitroprusside , NO donor , increase leg glucose uptake rest patient type 2 diabetes . Twenty male type 2 diabetic patient age 30 60 year recruit clinic advertisement . The inclusion criterion : - non-smokers - free overt coronary disease ( stress ECG ) - body mass index &lt; 35 kg.m-2 - fasting plasma glucose &gt; 7 mmol.L-1 / post 75 gm oral glucose load plasma glucose level &gt; 11.1 mmol.L-1 - unmedicated ( diet control ) The leg blood flow ( thermodilution ) glucose uptake response ( arterial-venous difference ) three cumulative dos sodium nitroprusside ( 0.1 , 0.3 0.6 ug.kg-1.min-1 , 10 min per dose ) infuse femoral artery use technique establish laboratory assess . Doses base extensive unpublished observation calculate lie linear part dose-response curve induce local systemic hemodynamic effect . As control also assess response nitrate independent vasodilator , Verapamil ( Isoptin ) ( 1 , 3 6 ug.kg-1.min-1 Doses ) . Verapamil calcium channel antagonist cause vasodilatation direct action smooth muscle . Doses titrate give similar blood flow response two drug administer randomize order 60 min wash-out period . Verapamil dos determine pilot experiment . Vastus lateralis biopsy perform baseline high dose drug cGMP GLUT-4 translocation measure . A single Vastus lateralis biopsy perform comparison type 2 diabetic . Significance : This study determine whether acute NO supplementation stimulate muscle GLUT-4 translocation glucose uptake patient type 2 diabetes . Pilot Study : To determine whether oral nitrate increase exhale NO level healthy volunteer &amp; compare isosorbide mononitrate ( ISMN ) pentaerythritol tetranitrate ( PETN ) determine drug effective increase exhale NO . Fifteen healthy male volunteer ( determine via medical screening ) age 18 65 year recruit advertisement . The inclusion criterion healthy control : - non-smokers - free overt coronary disease ( ECG ) - body mass index &lt; 30 kg.m-2 - fasting plasma glucose &lt; 6.1 mmol.L-1 - unmedicated Blood sample obtain oral glucose tolerance test ( OGTT ) perform . Baseline exhale nitric oxide ( NO ) pulmonary blood flow measure collaboration Dr Bruce Thompson Alfred Respiratory Department . Sodium nitroprusside ( SNP ) know NO donor use positive control . Following baseline measurement participant receive intravenous ( forearm vein ) infusion SNP ( titrate 0.3ug/kg/min maximum 3 ug/kg/min 30 minute ) . Blood pressure monitor throughout use automated sphygmomanometer . Post infusion exhale NO pulmonary blood flow measure . Participants commence second phase study determine whether ISMN PETN increase exhale NO level determine drug potent regard . Visit 2 , 3 &amp; 4 : Participants receive follow study medication randomise Latin square design : - Placebo administer morning Visit 2 , 3 4 , - extend release ISMN mononitrate ( 120mg ) administer morning Visit 2 , 3 4 ; &amp; - pentaerythritol tetranitrate ( 160mg administer morning Visit 2 , 3 4 ) . There 7-day wash-out period treatment/visit . Participants undergo repeat measure exhale NO , pulmonary blood flow OGTT three hour study drug administer . Blood take prior every hour participant take drug measurement NO metabolite ( e.g . nitrite/nitrate , nitrosothiols , nitrosohemoglobin ) . Nitrate drug occasionally associate headache dizziness . Headaches treat paracetamol . Endpoints baseline post treatment : - Post 75g oral glucose load - Exhaled NO level - Pulmonary blood flow Significance : Once effective NO donor determine utilized chronic nitrate study describe Aim 2 . Aim 2 : To determine whether chronic nitrate therapy 12 week improve glucose tolerance HbA1c patient type 2 diabetes . Twenty male type 2 diabetic subject age 30 60 year meet inclusion criterion specify Aim 1 recruit clinic advertisement . Patients randomize 12 week treatment long-acting nitrate therapy ( isosorbide mononitrate 60mg daily , Imdur ) placebo ( cross-over design ) . Primary endpoint : - glycated haemoglobin ( HbA1c ) - whole body glucose uptake rest ( stable glucose tracer methodology , ( 39-41 ) ) - whole body glucose uptake ( 0-2 hr ) 75 gm oral glucose load ( tracer methodology ) - skeletal muscle cGMP GLUT-4 translocation ( vastus lateralis muscle biopsy glucose load ) - skeletal muscle glycogen , lactate , phosphocreatine , creatine ATP Significance : This study determine whether chronic nitrate therapy increase GLUT-4 translocation / glucose uptake beneficial effect glycaemic control patient type 2 diabetes . Aim 3 : To determine whether acute infusion AICAR , AMP analogue , increase leg glucose uptake rest patient type 2 diabetes . Twenty healthy male twenty male type 2 diabetic age 30 60 year recruit clinic advertisement . The inclusion criterion diabetic : - non-smokers - free overt coronary disease ( stress ECG ) - body mass index &lt; 35 kg.m-2 - fasting plasma glucose &gt; 7 mmol.L-1 / post 75 gm oral glucose load plasma glucose level &gt; 11.1 mmol.L-1 - unmedicated ( diet control ) The leg blood flow ( thermodilution ) glucose uptake ( arterial-venous difference ) response 60 minute intra-femoral infusion AICAR ( 1 mg.kg-1.min-1 , Clinalfa , Switzerland ) use technique establish laboratory assess . As control also measure response vehicle ( saline ) infusion prior commence dose response curve ( 60 min ) . Plasma free fatty acid , glycerol , triglyceride lactate determine blood gas measure assess respiratory quotient . Vastus lateralis biopsy perform baseline AICAR follow parameter quantitated : - AMPK activity - nNOS phosphorylation - NOS activity - GLUT-4 translocation</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Nitroprusside</mesh_term>
	<criteria>Patients type 2 diabetes Nonsmokers Free overt coronary disease ( stress ECG ) Body mass index &lt; 35 kg.m2 Fasting plasma glucose &gt; 7 mmol.L1 / post 75 gm oral glucose load plasma glucose level &gt; 11.1 mmol.L1 Unmedicated ( diet control ) Healthy control Nonsmokers Free overt coronary disease ( ECG ) Body mass index &lt; 30 kg.m2 Fasting plasma glucose &lt; 6.1 mmol.L1 Unmedicated</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Blood Glucose</keyword>
	<keyword>Exercise</keyword>
	<keyword>Muscle Contraction</keyword>
	<keyword>Nitric Oxide</keyword>
	<keyword>Nitrates</keyword>
</DOC>